{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:18:59Z","timestamp":1760548739298},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1007\/s12094-008-0280-z","type":"journal-article","created":{"date-parts":[[2008,11,27]],"date-time":"2008-11-27T16:47:10Z","timestamp":1227804430000},"page":"739-744","source":"Crossref","is-referenced-by-count":2,"title":["Phase II study of dose-dense doxorubicin and docetaxel as neoadjuvant chemotherapy with G-CSF support in patients with large or locally advanced breast cancer"],"prefix":"10.1007","volume":"10","author":[{"given":"Jes\u00fas","family":"Garc\u00eda-Mata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s","family":"Garc\u00eda-Palomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lourdes","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ram\u00f3n","family":"Mel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Jes\u00fas","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,11,28]]},"reference":[{"issue":"[Suppl1]","key":"280_CR1","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1111\/j.1075-122X.2006.00205.x","volume":"12","author":"D.M. Parkin","year":"2006","unstructured":"Parkin DM, Fernandez LM (2006) Use of statistics to assess the global burden of breast cancer. Breast J 12[Suppl 1]:S70\u201380","journal-title":"Breast J"},{"key":"280_CR2","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1200\/JCO.1998.16.8.2672","volume":"16","author":"B. Fisher","year":"1998","unstructured":"Fisher B, Bryant J, Wolmark N et al (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672\u20132685","journal-title":"J Clin Oncol"},{"key":"280_CR3","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.1999.17.7.1999","volume":"17","author":"G. Minckwitz von","year":"1999","unstructured":"von Minckwitz G, Costa SD, Eiermann W et al (1999) Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel. J Clin Oncol 17:1999\u20132005","journal-title":"J Clin Oncol"},{"key":"280_CR4","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2005","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687\u20131717","journal-title":"Lancet"},{"key":"280_CR5","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1200\/JCO.2003.04.040","volume":"21","author":"J.M. Nabholtz","year":"2003","unstructured":"Nabholtz JM, Falkson C, Campos D et al (2003) Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 21:968\u2013975","journal-title":"J Clin Oncol"},{"key":"280_CR6","first-page":"35a","volume":"21","author":"J.R. Mackey","year":"2002","unstructured":"Mackey JR, Paterson A, Dirix LY et al (2002) Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclo phos phamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 21:35a","journal-title":"Proc Am Soc Clin Oncol"},{"key":"280_CR7","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1056\/NEJMoa043681","volume":"352","author":"M. Martin","year":"2005","unstructured":"Martin M, Pienkowski T, Mackey J et al (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302\u20132313","journal-title":"N Engl J Med"},{"key":"280_CR8","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1200\/JCO.2002.20.6.1456","volume":"20","author":"I.C. Smith","year":"2002","unstructured":"Smith IC, Heys SD, Hutcheon AW et al (2002) Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20:1456\u20131466","journal-title":"J Clin Oncol"},{"key":"280_CR9","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1200\/JCO.2003.12.005","volume":"21","author":"H.D. Bear","year":"2003","unstructured":"Bear HD, Anderson S, Brown A et al (2003) The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21:4165\u20134174","journal-title":"J Clin Oncol"},{"key":"280_CR10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1053\/sonc.2001.26435","volume":"28","author":"F.A. Holmes","year":"2001","unstructured":"Holmes FA, Rowinsky EK (2001) Pharmacokinetic profiles of doxorubicin in combination with taxanes. Semin Oncol 28:8\u201314","journal-title":"Semin Oncol"},{"key":"280_CR11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/sonc.2001.26434","volume":"28","author":"V. Valero","year":"2001","unstructured":"Valero V, Perez E, Dieras V (2001) Doxorubicin and taxane combination regimens for metastatic breast cancer: focus on cardiac effects. Semin Oncol 28:15\u201323","journal-title":"Semin Oncol"},{"key":"280_CR12","first-page":"S10-13","volume":"24","author":"L. Norton","year":"1997","unstructured":"Norton L (1997) Evolving concepts in the systemic drug therapy of breast cancer. Semin Oncol 24:S10-13\u2013S10-10","journal-title":"Semin Oncol"},{"issue":"[Suppl4]","key":"280_CR13","doi-asserted-by":"crossref","first-page":"iv31","DOI":"10.1093\/annonc\/mdh902","volume":"15","author":"L. Gianni","year":"2004","unstructured":"Gianni L, Mariani G, Mariani P (2004) Role of dose in the treatment of breast cancer. Ann Oncol 15[Suppl 4]:iv31\u201335","journal-title":"Ann Oncol"},{"key":"280_CR14","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","volume":"21","author":"M.L. Citron","year":"2003","unstructured":"Citron ML, Berry DA, Cirrincione C et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741\/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431\u20131439","journal-title":"J Clin Oncol"},{"key":"280_CR15","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1200\/JCO.2004.99.103","volume":"22","author":"B. Keith","year":"2004","unstructured":"Keith B, Hall R, Scholnik A (2004) Improved outcome with dose-dense chemotherapy. J Clin Oncol 22:749; author reply 751\u2013753","journal-title":"J Clin Oncol"},{"key":"280_CR16","unstructured":"(1999) Common Toxicity Criteria, Version 2.0. National Cancer Institute, Cancer Therapy Evaluation Program, Bethesda, MD, pp 1\u201327"},{"key":"280_CR17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P. Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"280_CR18","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1200\/JCO.2005.06.156","volume":"23","author":"T.R. Evans","year":"2005","unstructured":"Evans TR, Yellowlees A, Foster E et al (2005) Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an Anglo-Celtic Cooperative Oncology Group study. J Clin Oncol 23:2988\u20132995","journal-title":"J Clin Oncol"},{"key":"280_CR19","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1200\/JCO.2005.05.078","volume":"23","author":"G. Minckwitz von","year":"2005","unstructured":"von Minckwitz G, Raab G, Caputo A et al (2005) Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 23:2676\u20132685","journal-title":"J Clin Oncol"},{"key":"280_CR20","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1200\/JCO.1999.17.10.3033","volume":"17","author":"K.D. Miller","year":"1999","unstructured":"Miller KD, McCaskill-Stevens W, Sisk J et al (1999) Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol 17:3033\u20133037","journal-title":"J Clin Oncol"},{"key":"280_CR21","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1093\/annonc\/mdg449","volume":"14","author":"G. Ganem","year":"2003","unstructured":"Ganem G, Tubiana-Hulin M, Fumoleau P et al (2003) Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer. Ann Oncol 14:1623\u20131628","journal-title":"Ann Oncol"},{"key":"280_CR22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10549-005-9131-6","volume":"98","author":"S. Han","year":"2006","unstructured":"Han S, Kim SB, Kang SS et al (2006) A phase II study of neoadjuvant docetaxel plus doxorubicin (KBCS-01) in stage II, III breast cancer. Breast Cancer Res Treat 98:57\u201361","journal-title":"Breast Cancer Res Treat"},{"key":"280_CR23","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s10549-005-9125-4","volume":"97","author":"B.W. Cooper","year":"2006","unstructured":"Cooper BW, Radivoyevitch T, Overmoyer BA et al (2006) Phase II study of dose-dense sequential doxorubicin and docetaxel for patients with advanced operable and inoperable breast cancer. Breast Cancer Res Treat 97:311\u2013318","journal-title":"Breast Cancer Res Treat"},{"key":"280_CR24","first-page":"3889","volume":"47","author":"S.M. Swain","year":"1987","unstructured":"Swain SM, Sorace RA, Bagley CS et al (1987) Neo adjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res 47:3889\u20133894","journal-title":"Cancer Res"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-008-0280-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-008-0280-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-008-0280-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T18:40:57Z","timestamp":1589222457000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-008-0280-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["280"],"URL":"https:\/\/doi.org\/10.1007\/s12094-008-0280-z","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}